Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Steel Excel Inc. (ADPT) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/27/2021 GN Adaptive Biotechnologies to Present at the BofA Securities 2021 Virtual Healthcare Conference
03/17/2021 GN Adaptive Biotechnologies Strengthens Expertise and Diversity of Board of Directors with Appointments of Leslie Trigg and Katey Owen
03/05/2021 GN Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection
02/25/2021 GN Adaptive Biotechnologies to Present at the Cowen 41st Annual Healthcare Conference
02/23/2021 GN Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio
02/23/2021 GN Adaptive Biotechnologies Launches T-Detect™ COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection
01/11/2021 GN Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics
12/30/2020 GN Adaptive Biotechnologies to Present at the 39th Annual J.P. Morgan Healthcare Conference
12/06/2020 GN Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting
11/23/2020 GN Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
11/13/2020 GN Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections
11/10/2020 GN Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio
11/10/2020 GN Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results
10/13/2020 GN Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020
09/01/2020 GN Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference
08/10/2020 GN Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit
08/06/2020 GN Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia
08/04/2020 GN Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2
07/28/2020 GN Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease
07/15/2020 GN Adaptive Biotechnologies Announces Pricing of Public Offering of Common Stock
07/14/2020 GN Adaptive Biotechnologies Announces Proposed Public Offering of Common Stock
06/08/2020 GN UPDATE – Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
05/27/2020 GN Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
04/27/2020 GN Adaptive Biotechnologies to Report First Quarter Financial Results on May 12, 2020
04/09/2020 GN Adaptive Biotechnologies Expands Executive Leadership Team to Support Development and Commercialization of Clinical Products, including immunoSEQ Dx
02/19/2020 GN Adaptive Biotechnologies to Present at the 40th Annual Cowen Health Care Conference
01/13/2020 GN Adaptive and Genentech Partner to Use clonoSEQ® Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients
12/30/2019 GN Adaptive Biotechnologies to Present at the 38th Annual J.P. Morgan Healthcare Conference
12/09/2019 GN Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay
12/04/2019 GN Adaptive Biotechnologies and Collaborators to Present Data from More Than 25 clonoSEQ® Abstracts at ASH 2019 Demonstrating Clinical Relevance of Standardized, Accurate MRD Testing for Blood Cancer Patients
09/24/2019 GN Adaptive Biotechnologies Enters Partnership with Illumina to Develop Distributable IVD Test Kits for clonoSEQ and immunoSEQ Dx
08/13/2019 GN Adaptive Biotechnologies Corporation Reports Second Quarter 2019 Financial Results
08/07/2019 GN Adaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattle's Growing Biotech Hub
07/01/2019 GN Adaptive Biotechnologies Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy